BeiGene, Ltd.
https://www.beigene.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From BeiGene, Ltd.
Nurix’s BTK Protein Degrader Shows Early Promise In Lymphoma
The protein-degrader company has updated results in heavily pre-treated CLL and NHL patients, keeping it competitive with rival BeiGene.
Orphan Drugs – Slowdown Signals New Paths Ahead
Signs are that the rate of sales growth for orphan drugs is slowing but that does not mean that they have had their day. Far from it, finds a new report from Evaluate.
Orphan Drugs – Slowdown Signals New Paths Ahead
Signs are that the rate of sales growth for orphan drugs is slowing but that does not mean that they have had their day. Far from it, finds a new report from Evaluate.
BeiGene-Glenmark Deal Set Tevimbra, Brukinsa On India Trajectory
Glenmark to progress BeiGene’s key assets in India, a market where rival PD-1 inhibitors and BTK inhibitors have a head start. All eyes are on the regulatory pathway, which provides for a waiver of local trial requirements for new drugs on a case-by-case basis, subject to certain criteria.
Company Information
- Industry
- Biotechnology
- In Vitro Diagnostics
- Pharmaceuticals
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Bioinformatics
- Other Names / Subsidiaries
-
- MapKure, LLC
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice